mobitec-globe Innovative Tools for Molecular and Cell Biology

Post-Vaccination - Monitoring of Neutralizing Antibodies

Our partner VIDIA offers two new unique assays which are important for a comprehensive evaluation of the post-vaccination antibody response. These kits offer the opportunity to elucidate the quality of immune responses elicited after vaccination.

An advantage of the VIDITEST assays is the use of RBD (receptor-binding protein) antigen, which is a small peptide domain of the Spike protein that allows the virus to bind to the ACE2 (angiotensin-converting enzyme 2) receptor in human cells and then infect them. Only antibodies targeting specifically RBD are able to prevent SARS-CoV-2 binding to the cell. This is the goal of currently approved mRNA vaccines.

Spike protein plays a key role in detecting antibodies produced after vaccination. In particular, IgG antibodies against the S1 domain of the Spike protein may have a neutralizing function. Determining the level of neutralizing antibodies is one of the most important tools in evaluating the success of vaccination.

ELISA-VIDITEST anti-SARS-CoV-2 (RBD) IgG quanti

The test is intended for professional use for qualitative, semi-quantitative, and quantitative detection of IgG antibodies against the RBD protein of the coronavirus SARS-CoV-2 in human serum and plasma.

  • Quantitative detection of neutralizing IgG antibodies against RBD SARS-CoV-2 Spike protein (S1)
  • Quantification of results in standardized international units according to WHO (BAU/ml)
  • Monitoring of antibody response after mRNA vaccination with S1/RBD-based vaccines
  • Selection of convalescent plasma donors with neutralizing antibodies for immunotherapy of COVID-19 patients
  • CE-IVD certified

RAPID-VIDITEST anti-SARS-CoV-2 (RBD) IgG

Rapid chromatographic immunoassay for the qualitative detection of IgG antibodies against the receptor binding domain (RBD) of SARS-CoV-2 spike protein (S1) in human blood, serum, and plasma samples.

  • Qualitative detection of neutralizing IgG antibodies against RBD SARS-CoV-2 Spike protein (S1)
  • Rapid immunochromatographic test
  • Results within 10 minutes
  • Evaluation of the immune response after SARS-CoV-2 infection
  • Monitoring of antibody response after mRNA vaccination with S1/RBD-based vaccines
  • Selection of convalescent plasma donors with neutralizing antibodies for immunotherapy of COVID-19 patients
  • CE-IVD certified

Product Details: ELISA-VIDITEST anti-SARS-CoV-2 (RBD) IgG quanti

Product Details: RAPID-VIDITEST anti-SARS-CoV-2 (RBD) IgG

Related Products:

COVID-19 Drug Screening / Pseudovirus Neutralization Assay

Related products
ELISA-VIDITEST anti-SARS-CoV-2 (RBD) IgG quanti
Unit: 96 wells
661.00 € *
Rapid-VIDITEST SARS-CoV-2 (RBD) IgG
Unit: 20
162.00 € *
anti-SARS-CoV-2 (NP) IgA (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *
anti-SARS-CoV-2 (NP) IgG (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *
anti-SARS-CoV-2 (NP) IgM (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *
anti-SARS-CoV-2 (S1) IgA (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *
anti-SARS-CoV-2 (S1) IgG (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *
anti-SARS-CoV-2 (S1) IgM (Serum/Plasma), ELISA
Unit: 96 wells
661.00 € *